Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Amycretin UK status
Amycretin is a Novo Nordisk investigational single-molecule co-agonist of the GLP-1 and amylin receptors. Phase 1 results generated significant interest. It is not licensed anywhere as of mid-2026, and lawful UK access is via clinical trial only.
What amycretin is
Amycretin (Novo Nordisk code NN1213) is a single-molecule co-agonist that activates the GLP-1 receptor and the amylin receptor. Unlike CagriSema (which pairs two separate molecules in a single injection), amycretin is one molecule doing both jobs. Both subcutaneous and oral formulations have been reported.
The evidence so far
Phase 1 data — reported in 2024 and 2025 — indicated substantial weight-loss effects at the doses studied, including in trial arms where the comparator was placebo or low-dose semaglutide. Phase 2 trials are ongoing or starting; phase 3 follows.
Single-molecule co-agonists are an active area of development for metabolic disease. The commercial logic is simpler manufacturing and clearer regulatory pathway than combination products.
Lawful UK access
As an investigational drug, amycretin is only lawfully accessible in the UK through participation in a registered clinical trial. Trial activity has been at specialist endocrinology and obesity centres.
Grey-market warning
Some online suppliers have begun listing “research-grade amycretin” vials in 2025–26. For an early-stage investigational drug the grey-market risk profile is even worse than for established research peptides:
- No licensed reference product anywhere.
- Identity, concentration, and purity all unverifiable.
- Trial safety monitoring is what's producing the dose-finding and adverse-event picture; grey-market users are dosing entirely outside that monitoring.
- Early hype around phase 1 effect sizes creates strong demand and a fertile market for counterfeit or mis-identified product.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Amycretin — the next big GLP-1, available now”
‘Available now’ for an investigational drug not licensed anywhere means unregulated supply.
“Single-molecule co-agonist — better than CagriSema and Mounjaro”
Comparative claims for an early-stage investigational compound. Phase 1 effect sizes don't always survive phase 3.
“Compounded amycretin from our clinic”
Compounding an early-stage investigational drug outside trial scope isn't lawful UK ‘specials’ supply.
Sources & further reading
- NIHR — Be Part of Research — nihr.ac.uk
- ClinicalTrials.gov — clinicaltrials.gov
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk